#$%^&*AU2012216702B220141204.pdf#####C: NRPonb DCC WAMM$9Y3112_1 OC-69/2012 ABSTRACT The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, prematized or humanized antibodies or fragments, having altered ability to meditate cell signaling activity by a target antigen, and/or altered ability to meditate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modified ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.WO 2007/03 1875 PCTIIB2006/003294 - 24/ 28 C'C4 0 min IM I 0 D 00 C ~jUeewu oe6
